Understand the source comparison
Best Peptides for Cancer Research: Mechanism Comparison
Thymosin Alpha-1 TLR9 receptor activation in dendritic cells IL-12 upregulation → Th1 differentiation Phase III (adjuvant oncology) 42% increase in objective response rate when combined with checkpoint inhibitors Most evidence-backed immune modulator for combi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymosin Alpha-1
- TLR9 receptor activation in dendritic cells
- IL-12 upregulation → Th1 differentiation
- Phase III (adjuvant oncology)
- 42% increase in objective response rate when combined with checkpoint inhibitors
- Most evidence-backed immune modulator for combination therapy
- BPC-157
- VEGFR2 partial agonism
- VEGF-A/VEGFR2 disruption → reduced angiogenesis
- Preclinical (Phase I pending)
- 63% reduction in tumor vascularization in colon cancer xenografts
- Potent angiogenesis inhibitor with minimal systemic toxicity
- Epitalon
- hTERT downregulation in cancer cells
- Telomerase inhibition → replicative senescence
- Preclinical
- 78% reduction in hTERT mRNA in HeLa cells
- Selective telomerase modulation. Mechanism unclear but reproducible
- Selank
- Enkephalinase inhibition
- Microglial IL-6/TNF-alpha suppression
- Preclinical (neuro-oncology)
- 46% extension in median survival in glioblastoma models
- Neuroinflammation control in glioma. Underexplored but promising
- MK 677
- Ghrelin receptor agonism
- GH/IGF-1 axis modulation
- Phase II (cachexia)
- Preserves lean mass during chemotherapy. No direct anti-tumor effect
- Supportive care peptide for cachexia prevention, not tumor suppression